Laura Alonso Acero

Ms. Laura Alonso Acero

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2024 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
Matteo BoattiniMatteo Boattini
Matteo Boattini
Gabriele BiancoGabriele Bianco
Gabriele Bianco
LLLaura Iglesias Llorente
Laura Iglesias Llorente
LALaura Alonso Acero
Laura Alonso Acero
DNDaniel Nunes
Daniel Nunes
CCCristina Costa
Cristina Costa
The ESCPM group (Enterobacter species including Klebsiella aerogenes - formerly Enterobacter aerogenes, Serratia species, Citrobacter freundii complex, Providencia species and Morganella morganii) has not yet been incorporated into systematic surveillance programs. We conducted a multicentre retrospective observational study analysing all ESCPM strains isolated from blood cultures in 27 European hospitals over a three-year period (2020-2022). Diagnostic approach, epidemiology, and antimicrobial susceptibility were investigated. Our study comprised 6,774 ESCPM isolates. MALDI-TOF coupled to mass spectrometry was the predominant technique for bacterial identification. Susceptibility to new β-lactam/β-lactamase inhibitor combinations and confirmation of AmpC overproduction were routinely tested in 33.3% and 29.6% of the centres, respectively. The most prevalent species were E. cloacae complex (44.8%) and S. marcescens (22.7%). Overall, third-generation cephalosporins (3GC), combined third- and fourth-generation cephalosporins (3GC + 4GC) and carbapenems resistance phenotypes were observed in 15.7%, 4.6%, and 9.5% of the isolates, respectively. AmpC overproduction was the most prevalent resistance mechanism detected (15.8%). Among carbapenemase-producers, carbapenemase type was provided in 44.4% of the isolates, VIM- (22.9%) and OXA-48-enzyme (16%) being the most frequently detected. E. cloacae complex, K. aerogenes and Providencia species exhibited the most notable cumulative antimicrobial resistance profiles, with the former displaying 3GC, combined 3GC + 4GC and carbapenems resistance phenotypes in 15.2%, 7.4%, and 12.8% of the isolates, respectively. K. aerogenes showed the highest rate of both 3GC resistant phenotype (29.8%) and AmpC overproduction (32.1%), while Providencia species those of both carbapenems resistance phenotype (42.7%) and carbapenemase production (29.4%). ESCPM isolates exhibiting both 3GC and combined 3GC + 4GC resistance phenotypes displayed high susceptibility to ceftazidime/avibactam (98.2% and 95.7%, respectively) and colistin (90.3% and 90.7%, respectively). Colistin emerged as the most active drug against ESCPM species (except those intrinsically resistant) displaying both carbapenems resistance phenotype (85.8%) and carbapenemase production (97.8%). This study presented a current analysis of ESCPM species epidemiology in Europe, providing insights to inform current antibiotic treatments and guide strategies for antimicrobial stewardship and diagnostics.

14 November 2023 in Enfermedades Infecciosas y Microbiología Clínica
Verified
Journal Article
Closed access
IBIván Bloise-Sánchez
Iván Bloise-Sánchez
LALaura Alonso Acero
Laura Alonso Acero

30 July 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
Sergio Ruiz-SantanaSergio Ruiz-Santana
Sergio Ruiz-Santana
JRJosé Dearriba Reyes
José Dearriba Reyes
PSPedro Saavedra
Pedro Saavedra
LLLaura Iglesias Llorente
Laura Iglesias Llorente
LALaura Alonso Acero
Laura Alonso Acero
CSCatalina Sánchez-Ramírez
Catalina Sánchez-Ramírez
Background: Antibiotic resistance is a worldwide concern. This study retrospectively analyzed patients admitted to the ICU of a tertiary hospital over a period of 7 months who were rectally colonized by multidrug-resistant microorganisms. The incidence of concomitant nosocomial infections was estimated, thus providing the risk of a colonizing microorganism producing a nosocomial infection. Methods: Infections with the same microorganism (concomitant) or different microorganisms (non-concomitant) were analyzed in order to adjust the empirical antibiotic treatment. Patients with rectal colonization by at least one multidrug-resistant bacterium (MDRB) on admission or after ICU admission were included. All patients had complete selective digestive decontamination (SDD) prophylaxis. For univariate analysis, categorical variables are expressed as frequencies and percentages and continuous variables as means and standard deviations, or as medians and interquartile ranges. For multivariate analysis, the model is summarized with p-values and hazard ratios with 95% confidence intervals. Survival analysis was conducted using the Kaplan–Meier method, which was performed to evaluate the time elapsed from colonization to infection by the same bacteria. Statistical significance was considered at p < 0.05. Results: Of the 130 patients with MDRB bacterial colonization analyzed, 98 remained free of infection, while 22 developed non-concomitant infections and 10 had infections concomitant to rectal colonizing bacteria. OXA-48-producing bacteria and MDR-Pseudomonas spp. incidences were 18.9% (95% CI: 7.96–35.2) and 44.4% (CI: 13.7–78.8), respectively. Conclusions: OXA-48-producing bacteria and MDR-Pseudomonas spp. were the only bacteria associated with the development of infections concomitant to rectal colonization in an SDD setting. The incidence of MDRB infections was low.

1 February 2022 in Enfermedades Infecciosas y Microbiología Clínica
Verified
Journal Article
Closed access
LALaura Alonso Acero
Laura Alonso Acero
EVEloy José Tarín Vicente
Eloy José Tarín Vicente
ECElena Sendagorta Cudos
Elena Sendagorta Cudos
MGMaría Pilar Romero Gómez
María Pilar Romero Gómez

28 July 2026 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
MFMiguel Fernández-Huerta
Miguel Fernández-Huerta
ELEduardo Lagarejos
Eduardo Lagarejos
IHIballa Horcajada
Iballa Horcajada
LFLaura Florén-Zabala
Laura Florén-Zabala
LALaura Alonso Acero
Laura Alonso Acero
ABAna Bordes-Benítez
Ana Bordes-Benítez

12 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
FRFrancisco Acoidan Rodríguez-Batista
Francisco Acoidan Rodríguez-Batista
JMJose Luis Martín-Barrasa
Jose Luis Martín-Barrasa
RCRuth Henríquez Cabrera
Ruth Henríquez Cabrera
CMCarlos José Martel-Benítez
Carlos José Martel-Benítez
RARafael Alayon Afonso
Rafael Alayon Afonso
JFJose Luis Hernandez Fleta
Jose Luis Hernandez Fleta
Major depressive disorder pathophysiology involves complex gut-brain axis interactions, yet the systemic non-neurochemical impacts of selective serotonin reuptake inhibitors re-main poorly defined. This study evaluated the multidimensional effects of chronic fluoxe-tine administration in Sprague-Dawley rats. Male rats received fluoxetine (10 mg/kg/day) or water for 60 days, followed by behavioral phenotyping, fecal microbiological quantifi-cation, serum biochemistry, complete blood count analysis, and immunohistochemical assessment of the immediate-early gene product c-Fos (cellular proto-oncogene protein) in the striatum. Fluoxetine treatment significantly reduced immobility time in the forced swim test, whereas object recognition memory deteriorated without alterations in anxie-ty-like behavior. Pharmacological intervention markedly depleted fecal bacterial popula-tions and significantly decreased serum vitamin D concentrations. Hematologically, treated animals exhibited significant reductions in total leukocytes, red blood cells, and platelets, alongside elevated hematocrit and mean corpuscular volume. Concurrently, c-Fos-positive neuronal activation increased significantly within the striatal nucleus ac-cumbens. In conclusion, chronic fluoxetine exposure induces profound systemic disrup-tion, altering gut microbial homeostasis, depleting vitamin D, and modulating peripheral blood profiles while enhancing central striatal neuronal plasticity. These findings under-score the necessity of monitoring gut-brain axis integrity during prolonged antidepressant therapy.